Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamideShannon R. McCurdy, Yvette L. Kasamon, Gary L. Rosner et al.|Blood|2015Cited by 299
Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamideShannon R. McCurdy, Leo Luznik, Yvette L. Kasamon et al.|Haematologica|2016Cited by 187
Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adultsHeather J. Symons, Ephraim J. Fuchs, Marianna Zahurak et al.|Blood Advances|2020Cited by 73
Blinatumomab in Combination with Immune Checkpoint Inhibitors of PD-1 and CTLA-4 in Adult Patients with Relapsed/Refractory (R/R) CD19 Positive B-Cell Acute Lymphoblastic Leukemia (ALL): Preliminary Results of a Phase I StudyJonathan Webster, Ivana Gojo, Marlise R. Luskin et al.|Blood|2018Cited by 50
A PBD-dimer containing antibody drug conjugate targeting CCRL2 for high-risk MDS/AMLNour Sabiha Naji, Theodoros Karantanos, Taha Ahmedna et al.|bioRxiv (Cold Spring Harbor Laboratory)|2025Cited by 1